VirtualScopics Completes 6 week Analysis of Phase III Breast Cancer Study

  VirtualScopics Completes 6 week Analysis of Phase III Breast Cancer Study

Utilization of 3rd generation analysis platform enables delivery of 2 million
records 1 week ahead of schedule

PR Newswire

ROCHESTER, N.Y., June 27, 2013

ROCHESTER, N.Y., June 27, 2013 /PRNewswire/ --VirtualScopics, Inc.
(NASDAQ:VSCP), a leading provider of quantitative imaging, today announced
that they have completed analysis of a greater than 10,000 scan Phase III
breast cancer study one week ahead of the six week contract period of the
study utilizing a recently launched 3^rd generation analysis platform.

Details of this new system include:

  oSignificant advances in radiology productivity enabling shorter timelines
    and reduced cost.
  oAn automated case check feature that validates radiologist input according
    to the technical details of analysis criteria and detects errors in
    real-time reducing rework and enhancing first pass quality.
  oA one-touch, automated data management system ensuring complete data
    integrity from receipt to delivery reducing the need for data
    reconciliation and allowing for compressed timelines, a critical element
    for late phase studies.
  oSignificant enhancements in our Phase III capacity and quality control
    processes, facilitating increased revenue growth, client satisfaction, and
    financial return.

Jeff Markin, president and chief executive officer of VirtualScopics stated,
"We are extremely pleased to have finished this very large time compressed
study ahead of schedule. The analysis represented in this study is the last
remaining piece of efficacy data required for the client's submission to the
regulatory authorities. As such, it was very important for us to complete
this with the highest possible quality at or ahead of schedule." He further
stated, "This study, along with regularly contracted work completed during the
same period, represented a greater than 300% increase in the quantity of data
ever processed by the company in a five week timeframe. I am very proud of
our team for completing this ahead of schedule including a results file with
over 2 million records with no data errors identified by the client or their
data management company." He concluded, "As we process and pursue additional
large studies like this our personnel, software, and systems positions us very
well from a client and financial perspective."

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate
drug and medical device development. VirtualScopics has developed a robust
software platform for analysis and modeling of both structural and functional
medical images. In combination with VirtualScopics' industry-leading
experience and expertise in advanced imaging biomarker measurement, this
platform provides a uniquely clear window into the biological activity of
drugs and devices in clinical trial patients, allowing sponsors to make better
decisions faster. For more information about VirtualScopics, visit

Forward-Looking Statements

The statements contained in this press release that are not purely historical
are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities Exchange
Act of 1934, as amended, and are intended to be covered by the safe harbors
created thereby. These forward-looking statements include, but are not limited
to, statements regarding the expected benefits of the Company's investment in
infrastructure and new customer contract signings and awards and/or statements
preceded by, followed by or that include the words "believes," "could,"
"expects," "anticipates," "estimates," "intends," "plans," "projects,"
"seeks," or similar expressions. Forward-looking statements deal with the
Company's current plans, intentions, beliefs and expectations. Investors are
cautioned that all forward-looking statements involve risks and uncertainties
that could cause actual results to differ materially from those in the
forward-looking statements. Many of these risks and uncertainties are
discussed in the Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2012 filed with the Securities and Exchange Commission (the
"SEC"), and in any subsequent reports filed with the SEC, all of which are
available at the SEC's website at These include without
limitation: the risk of cancellation or delay of customer contracts or
specifically as it relates to contact awards, the risk that they may not get
signed. Other risks include the company's dependence on its largest customers
and risks of contract performance, protection of our intellectual property and
the risks of infringement of the intellectual property rights of others. All
forward-looking statements speak only as of the date of this press release and
the Company undertakes no obligation to update such forward-looking

CONTACTS: Investor Relations:        Company Contact:
          Tim Ryan                   Molly Henderson
          The Shoreham Group         Chief Business and Financial Officer, Sr.
                                     Vice President
          80 Eighth Ave, Ste 1107    500 Linden Oaks
          New York, NY 10011         Rochester, New York 14625
          +1 212 242 7777 Direct     +1 585 249.6231

SOURCE VirtualScopics, Inc.

Press spacebar to pause and continue. Press esc to stop.